| Adm | 25026 | Protein administration | Accelerated wound closure | 
			
				
					| Adrb1 | 24925 | Antagonist administration | Delayed contraction in propranolol- and atenolol-treated animals but not in phentolamine-treated animals; re-epithelialization was decreased only in propranolol-treated animals | 
			
				
					| Adrb2 | 24176 | Antagonist administration | Delayed contraction in propranolol- and atenolol-treated animals but not in phentolamine-treated animals; re-epithelialization was decreased only in propranolol-treated animals | 
			
				
					| Agt | 24179 | Protein administration | Accelerated wound closure | 
			
				
					| Ankrd1 | 27064 | Overexpression | Increased vascular component in granulation tissue | 
			
				
					| C3 | 24232 | Protein administration | Increased maximal breaking strength; increased fibroblast and collagen deposition; additive hemostatic effect with the C3C5 combination | 
			
				
					| C5 | 362119 | Protein administration | Increased maximal breaking strength; accelerated wound healing; increased vascular permeability, increased inflammatory cell recruitment, subsequent fibroblast migration, and increased collagen deposition | 
			
				
					| C5 | 362119 | Protein administration | Increased maximal breaking strength; increased fibroblast and collagen deposition; additive hemostatic effect with the C3C5 combination | 
			
				
					| Cfh | 155012 | Protein administration | Accelerated wound closure | 
			
				
					| Egf | 25313 | Overexpression | Flap survival was enhanced by 14%, and was accomplished without accessing the arterial inflow of the territory | 
			
				
					| Egf | 25313 | Protein administration | Accelerated wound closure; Accelerated epidermal proliferation | 
			
				
					| Egf | 25313 | Protein administration | Promotion of wound healing | 
			
				
					| Egf | 25313 | Protein administration | Accelerated re-repithelialization | 
			
				
					| Epo | 24335 | Protein administration, antibody treatment | Protein administration: Increased granulation tissue formationr; Receptor or neutralizing antibody administration: inhibited granulation tissue formation | 
			
				
					| Epor | 24336 | Protein administration, antibody treatment | Protein administration: Increased granulation tissue formationr; Receptor or neutralizing antibody administration: inhibited granulation tissue formation | 
			
				
					| F2 | 29251 | Peptide administration | Accelerated wound closure in both normal and ischemic skin | 
			
				
					| Fgf10 | 25443 | Protein administration | Accelerated re-epithelialization in the meshed skin graft model; more rapid gain in breaking strength of surgical incisions | 
			
				
					| Fgf2 | 54250 | Protein administration | Increased α-SMA up to day 18 and then caused a decrease | 
			
				
					| Fgf2 | 54250 | Antibody treatment | Reduced collagen content | 
			
				
					| Fgf7 | 29348 | Overexpression (liposomal gene transfer) | Increased re-epithelialization; improved dermal regeneration; increased neovascularization | 
			
				
					| Hgf | 24446 | Protein administration | Accelerated re-epithelialization in diabetic rats; increased expressions of the cell adhesion molecules β1-integrin and the cytoskeleton remodeling protein integrin-linked kinase (ILK) in epidermal cells | 
			
				
					| Hpse | 64537 | Protein administration | Accelerated wound healing and improved FLAP survival; enhanced wound re-epithelialization and blood vessel maturation | 
			
				
					| Igf1 | 24482 | Overexpression (in exogenous fibroblasts) | More organised granulation tissue formation; increased number of keratinocytes | 
			
				
					| Igf1 | 24482 | Overexpression (liposomal gene transfer) | Improved dermal regeneration by an increased collagen deposition and morphology; increased VEGF concentrations and neovascularization | 
			
				
					| Itgb2 | 309684 | Antibody treatment | Improved flap survival; decreased dermal and anastomotic myeloperoxidase activity | 
			
				
					| Lama3 | 307582 | Peptide administration | Accelerated re-epithelialization; reduced inflammatory cell infiltration; enhanced fibroblast proliferation | 
			
				
					| Lep | 25608 | Protein administration | Increased granulation tissue; improved angiogenesis; better flap survival | 
			
				
					| Lox | 24914 | Gene activated matrix | Enhanced mechanical strength of the wound site | 
			
				
					| Mmp8 | 63849 | Overexpression | Impaired wound healing by decreased collagen deposition and breaking strength; decreased number of neutrophils | 
			
				
					| Ngf | 310738 | Protein administration | Accelerated wound healing, re-epithelialization, formation of granulation tissue, and collagen production | 
			
				
					| Pdgfb | 24628 | Protein administration | Accelerated wound healing; Accelerated degradation of the polymer and enhanced formation of new granulation tissue as early as day 3 | 
			
				
					| Proc | 25268 | Protein administration | Enhanced wound healing | 
			
				
					| Tgfb1 | 59086 | Antibody treatment, protein administration | Neutralising TGF-beta 1: reduced the monocyte and macrophage profile, neovascularisation, fibronectin, collagen III and collagen I deposition in the early stages of wound healing; improved the architecture of the neodermis to resemble that of normal dermis and reduced scarring; effect was stronger when comined with TG-beta 2 neutralization; Protein treatment: more extracellular matrix deposition in the early stages of wound healing but did not differ from control wounds in the final quality of scarring | 
			
				
					| Tgfb1 | 59086 | Protein administration | Accelerated wound healing; Increased wound breaking strength; increased influx of mononuclear cells and fibroblasts; increases in collagen deposition | 
			
				
					| Tgfb2 | 81809 | Antibody treatment, protein administration | Neutralising TGF-beta 2 alone had no effect; combined with TGF-beta 1, it reduced the monocyte and macrophage profile, neovascularisation, fibronectin, collagen III and collagen I deposition in the early stages of wound healing; markedly improved the architecture of the neodermis to resemble that of normal dermis and reduced scarring; by contrast, wounds treated with either TGF-beta 1 or with TGF-beta 2 had more extracellular matrix deposition in the early stages of wound healing but did not differ from control wounds in the final quality of scarring | 
			
				
					| Tgfb3 | 25717 | Protein administration | Reduced the monocyte and macrophage profile, fibronectin, collagen I and collagen III deposition in the early stages of wound healing and improved the architecture of the neodermis and reduced scarring | 
			
				
					| Tgfbr2 | 81810 | Overexpression | Inhibited inflammatory reaction with reduced inflammatory cells; reduced scarring area | 
			
				
					| Tmsb4x | 81814 | protein dimer administration | Accelerated wound healing | 
			
				
					| Vegfa | 83785 | Overexpression (local plasmid injection) | Increased skin flap perfusion; increase in skin flap healing and survival |